Latest Government Grants News

Page 2 of 58
Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
Victor Sage
Victor Sage
30 Oct 2026
A US$1.536 million US Government grant will fund a two-year campaign to attract investment, commercial partners and engineering expertise to PhosCo’s Gasaat phosphate project in Tunisia. The opportunity is significant, but the money goes to adviser CrossBoundary and does not guarantee funding for PhosCo.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Osmond Resources has advanced its Spanish critical minerals project through a maiden resource, a striking but preliminary scoping study and a maximum government grant. Yet with A$3.15 million in cash against a development concept requiring US$299 million, financing remains the project’s defining test.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Blue Energy is positioning its Queensland gas portfolio for potential demand from LNG exporters under proposed federal reservation rules, while seeking a farm-in partner for ATP 854. The company ended September with A$3.2 million in unaudited cash, no debt and a more cautious approach to Sapphire spending.
Victor Sage
Victor Sage
30 Oct 2026
Heavy Minerals has delivered a maiden Ore Reserve and a A$322.8 million post-tax NPV for Port Gregory, while Kanmantoo engineering advances toward a Final Investment Decision. The projects now have more defined technical foundations, but the company’s cash position and non-binding funding discussions leave execution as the central question.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Vulcan Energy’s first matrix reinjection well delivered an estimated 64 standard litres per second, above the 40-litre assumption underpinning Lionheart’s development plan. The technical progress came alongside €98.0 million of quarterly investing outflows and a cash balance of €129.4 million ahead of expected project debt drawdown in Q1 2027.
Victor Sage
Victor Sage
30 Oct 2026
Sprintex has moved its €25.71 million Mest Water order book into commercial manufacturing after receiving A$1.3 million in customer payments. The progress comes alongside a sharply constrained funding position, with A$166,000 in cash and estimated funding of just 0.17 quarters at September-end.
Victor Sage
Victor Sage
29 Oct 2026
Li-S Energy has delivered its lithium-sulfur Power Cells to a US Army research centre and completed a near two-hour endurance flight with its Pegasus drone. The milestones advance its defence and aerospace commercialisation pipeline, but neither has yet produced a procurement order or confirmed revenue.
Victor Sage
Victor Sage
29 Oct 2026
Great Boulder Resources has completed more than 57,000 metres of drilling across Peak Hill and Side Well during the September quarter, with high-grade results supporting potential resource growth. The ASX-listed explorer ended the period with A$12.3 million in cash and no debt as it works towards a Peak Hill resource update by year-end.
Maxwell Dee
Maxwell Dee
29 Oct 2026
PainChek is concentrating its commercial effort on residential aged care after signing new US and UK business, including an 808-licence Sabra expansion and an approximately 1,800-licence Hallmark contract. Revenue and retention improved, but activated ARR growth slowed to 1.2% for the quarter and cash covered an estimated 2.5 quarters of historical operating outflows.
Victor Sage
Victor Sage
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026

Browse the archive

Full archive